Cargando…
The clinical efficacy of epalrestat combined with α-lipoic acid in diabetic peripheral neuropathy: Protocol for a systematic review and meta-analysis
BACKGROUND: Diabetic peripheral neuropathy (DPN) is a common long-term complication of diabetes mellitus, affecting patients in the world. Epalrestat combined with α-lipoic acid (ALA) is the most frequent combine therapy used in the DPN researches. We aim to assess the effectiveness and safety of ep...
Autores principales: | Wang, Xiaotong, Lin, Haixiong, Xu, Shuai, Jin, Yuanlin, Zhang, Ren |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5944676/ https://www.ncbi.nlm.nih.gov/pubmed/29419686 http://dx.doi.org/10.1097/MD.0000000000009828 |
Ejemplares similares
-
Alpha lipoic acid combined with epalrestat: a therapeutic option for patients with diabetic peripheral neuropathy
por: Wang, Xiaotong, et al.
Publicado: (2018) -
Efficacy of epalrestat plus α-lipoic acid combination therapy versus monotherapy in patients with diabetic peripheral neuropathy: a meta-analysis of 20 randomized controlled trials
por: Zhao, Ming, et al.
Publicado: (2018) -
Efficacy, safety, and tolerability of Epalrestat compared to Methylcobalamine in patients with diabetic neuropathy
por: Maladkar, Manish, et al.
Publicado: (2009) -
Epalrestat protects against diabetic peripheral neuropathy by alleviating oxidative stress and inhibiting polyol pathway
por: Li, Qing-rong, et al.
Publicado: (2016) -
Epalrestat, an aldose reductase inhibitor, in diabetic neuropathy: An Indian perspective
por: Sharma, S. R., et al.
Publicado: (2008)